Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Merck & Co., Inc.MRK · Entity 2807 | Director | May 26, 2017 | May 30, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Merck & Co., Inc.
Report date May 26, 2017 · Filed May 30, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom StockSEC Table II · derivative / convertible security | Direct | 33,755.2025 |
Reported balance
After 2017-05-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-05-26 · Grant · Acquired 2,618.6075 · Balance 33,755.2025 F1: 1-for-1 F2: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3: Holdings include shares acquired in dividend reinvestment transactions. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 11,500 |
Reported balance
Holding disclosure · report date 2017-05-26 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 11,500 |
Filing footnotes · ownership attribution and instrument terms
F1: 1-for-1
F2: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.
F3: Holdings include shares acquired in dividend reinvestment transactions.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 26, 2017 Filed May 30, 2017 21:33 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 2,618.6075 | $64.92 | $170,000.00 |
DisclosureSEC source: 0001225208-17-010557 · doc4.xml · derivative · entry 2 REPRESAS CARLOS E · CIK 0001216083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,755.2025 Underlying: Common Stock · 2,618.6075 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 27, 2016 Filed May 31, 2016 19:56 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 3,009.915 | $56.48 | $170,000.00 |
DisclosureSEC source: 0001225208-16-034170 · doc4.xml · derivative · entry 3 REPRESAS CARLOS E · CIK 0001216083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,213.269 Underlying: Common Stock · 3,009.915 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 29, 2015 Filed Jun 1, 2015 18:50 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 2,463.4587 | $60.89 | $150,000.00 |
DisclosureSEC source: 0001225208-15-013059 · doc4.xml · derivative · entry 3 REPRESAS CARLOS E · CIK 0001216083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,298.1807 Underlying: Common Stock · 2,463.4587 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| August 01, 2014 Filed Aug 5, 2014 14:16 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $35.19 | $0.00 |
DisclosureSEC source: 0001225208-14-017934 · doc4.xml · derivative · entry 3 REPRESAS CARLOS E · CIK 0001216083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2020-08-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option became exercisable in equal installments on 8/4/2011, 8/4/2012 and 8/4/2013. Read SEC document |
| August 01, 2014 Filed Aug 5, 2014 14:16 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 5,000 | $35.19 | $175,950.00 |
DisclosureSEC source: 0001225208-14-017934 · doc4.xml · nonDerivative · entry 1 REPRESAS CARLOS E · CIK 0001216083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 30, 2014 Filed Jun 3, 2014 17:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 2,592.4646 | $57.86 | $150,000.00 |
DisclosureSEC source: 0001225208-14-014284 · doc4.xml · derivative · entry 3 REPRESAS CARLOS E · CIK 0001216083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,130.0346 Underlying: Common Stock · 2,592.4646 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| November 04, 2013 Filed Nov 4, 2013 21:33 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 3,334 | $0.00 Strike: $24.30 | $0.00 |
DisclosureSEC source: 0001225208-13-022799 · doc4.xml · derivative · entry 3 REPRESAS CARLOS E · CIK 0001216083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,334 shares Expires 2019-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vests in three equal annual installments beginning May 1, 2010. Read SEC document |
| November 04, 2013 Filed Nov 4, 2013 21:33 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 3,334 | $24.30 | $81,016.20 |
DisclosureSEC source: 0001225208-13-022799 · doc4.xml · nonDerivative · entry 1 REPRESAS CARLOS E · CIK 0001216083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,834 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 31, 2013 Filed Jun 3, 2013 19:07 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 3,211.9914 | $46.70 | $150,000.00 |
DisclosureSEC source: 0001225208-13-013653 · doc4.xml · derivative · entry 3 REPRESAS CARLOS E · CIK 0001216083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,837.0024 Underlying: Common Stock · 3,211.9914 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 25, 2012 Filed May 29, 2012 19:22 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 3,994.6738 | $37.55 | $150,000.00 |
DisclosureSEC source: 0001225208-12-013297 · doc4.xml · derivative · entry 3 REPRESAS CARLOS E · CIK 0001216083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,995.8368 Underlying: Common Stock · 3,994.6738 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 27, 2011 Filed May 31, 2011 14:45 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 4,142.5021 | $36.21 | $150,000.00 |
DisclosureSEC source: 0001225208-11-015341 · doc4.xml · derivative · entry 3 REPRESAS CARLOS E · CIK 0001216083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,483.617 Underlying: Common Stock · 4,142.5021 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| March 31, 2011 Filed Apr 1, 2011 12:59 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 833.0809 | $33.01 | $27,500.00 |
DisclosureSEC source: 0001225208-11-010583 · doc4.xml · derivative · entry 3 REPRESAS CARLOS E · CIK 0001216083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,267.7529 Underlying: Common Stock · 833.0809 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| December 31, 2010 Filed Jan 3, 2011 17:52 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 617.3696 | $36.04 | $22,250.00 |
DisclosureSEC source: 0001225208-11-000085 · doc4.xml · derivative · entry 3 REPRESAS CARLOS E · CIK 0001216083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,376.0811 Underlying: Common Stock · 617.3696 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| November 17, 2010 Filed Nov 18, 2010 20:27 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 1,666 | $0.00 Strike: $24.30 | $0.00 |
DisclosureSEC source: 0001225208-10-025214 · doc4.xml · derivative · entry 2 REPRESAS CARLOS E · CIK 0001216083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,334 Underlying: Common Stock · 1,666 shares Expires 2019-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vests in three equal annual installments beginning May 1, 2010. Read SEC document |
| November 17, 2010 Filed Nov 18, 2010 20:27 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 1,666 | $24.30 | $40,483.80 |
DisclosureSEC source: 0001225208-10-025214 · doc4.xml · nonDerivative · entry 1 REPRESAS CARLOS E · CIK 0001216083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,166 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 17, 2010 Filed Jan 20, 2011 21:36 UTC Amendment | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 1,666 | $24.30 | $40,483.80 |
DisclosureSEC source: 0001225208-11-003443 · doc4a.xml · nonDerivative · entry 1 REPRESAS CARLOS E · CIK 0001216083 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 2,666 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This amended Form 4 is being filed to correct the Form 4 filed on November 18, 2010 in which the acquisition of 1,666 shares should have been credited to Mr. Represas' Indirect holdings by Trust rather than direct holdings. Read SEC document |
| September 30, 2010 Filed Oct 1, 2010 21:08 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 685.9549 | $36.81 | $25,250.00 |
DisclosureSEC source: 0001225208-10-021738 · doc4.xml · derivative · entry 2 REPRESAS CARLOS E · CIK 0001216083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,706.7395 Underlying: Common Stock · 685.9549 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| August 04, 2010 Filed Aug 6, 2010 14:55 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $35.19 | $0.00 |
DisclosureSEC source: 0001225208-10-018705 · doc4.xml · derivative · entry 2 REPRESAS CARLOS E · CIK 0001216083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2020-08-03 F1 · derivative.exercise_date: The option vests in three equal annual installments beginning August 4, 2011. Read SEC document |
| June 30, 2010 Filed Jul 1, 2010 18:15 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 636.2597 | $34.97 | $22,250.00 |
DisclosureSEC source: 0001225208-10-015979 · doc4.xml · derivative · entry 2 REPRESAS CARLOS E · CIK 0001216083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,974.8096 Underlying: Common Stock · 636.2597 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 28, 2010 Filed Jun 1, 2010 20:00 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 1,632.5319 | $33.69 | $55,000.00 |
DisclosureSEC source: 0001225208-10-014288 · doc4.xml · derivative · entry 2 REPRESAS CARLOS E · CIK 0001216083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,338.5499 Underlying: Common Stock · 1,632.5319 shares Expires not disclosed F1 · derivative.exercise_price: 1-for-1 F2 · derivative.exercise_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F2 · derivative.expiration_date: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| November 03, 2009 Filed Nov 6, 2009 02:35 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $24.30 | $0.00 |
DisclosureSEC source: 0001225208-09-021805 · doc4.xml · derivative · entry 3 REPRESAS CARLOS E · CIK 0001216083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2019-04-30 F3 · price: This option, which vests in three equal annual installments beginning one year from date of grant, was assumed in the Transaction and continued on the same terms and conditions for an option to purchase an equivalent number of shares of MSD common stock at the same exercise price as applied prior to the merger. Read SEC document |
| November 03, 2009 Filed Nov 6, 2009 02:35 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantPhantom Stock · Derivative | 2,651.6274 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-09-021805 · doc4.xml · derivative · entry 2 REPRESAS CARLOS E · CIK 0001216083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,651.6274 Underlying: Common Stock · 2,651.6274 shares Expires not disclosed F2 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of Merck & Co., Inc. Common Stock, pursuant to the Plan for Deferred Payment of Directors Compensation, and was exchanged for an equal number of shares of phantom stock of MSD in connection with the Transactions. F2 · derivative.exercise_date: Each share of phantom stock is the economic equivalent of one share of Merck & Co., Inc. Common Stock, pursuant to the Plan for Deferred Payment of Directors Compensation, and was exchanged for an equal number of shares of phantom stock of MSD in connection with the Transactions. F2 · derivative.expiration_date: Each share of phantom stock is the economic equivalent of one share of Merck & Co., Inc. Common Stock, pursuant to the Plan for Deferred Payment of Directors Compensation, and was exchanged for an equal number of shares of phantom stock of MSD in connection with the Transactions. Read SEC document |
| November 03, 2009 Filed Nov 6, 2009 02:35 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-09-021805 · doc4.xml · nonDerivative · entry 1 REPRESAS CARLOS E · CIK 0001216083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 F1 · price: Received in exchange for an equivalent number of shares of Merck Sharp & Dohme Corp. (formerly Merck & Co., Inc.) ("MSD") common stock in connection with the completion of transactions contemplated by the Agreement and Plan of Merger by and among, inter alia, MSD and Merck & Co., Inc. (formerly Schering-Plough Corporation) (the "Transactions"). Read SEC document |
| November 03, 2009 Filed Nov 22, 2010 21:29 UTC Amendment | Merck & Co., Inc. MRK · Entity 2807 | OtherCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-10-025382 · doc4a.xml · nonDerivative · entry 1 REPRESAS CARLOS E · CIK 0001216083 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 1,000 F1 · balance_after: This amended Form 4 is being filed to report a family trust inadvertently omitted on the original filing. Read SEC document |
| November 03, 2009 Filed Jan 20, 2011 20:35 UTC Amendment | Merck & Co., Inc. (MRK) · Entity 2807 | GrantCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-11-004139 · doc4a.xml · nonDerivative · entry 2 REPRESAS CARLOS E · CIK 0001216083 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 1,000 F1 · shares: This amended Form 4 is being filed to correct the amended Form 4 filed on 11/22/2010. Read SEC document |
| November 03, 2009 Filed Jan 20, 2011 20:35 UTC Amendment | Merck & Co., Inc. (MRK) · Entity 2807 | GrantCommon Stock | 500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-11-004139 · doc4a.xml · nonDerivative · entry 1 REPRESAS CARLOS E · CIK 0001216083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 F1 · shares: This amended Form 4 is being filed to correct the amended Form 4 filed on 11/22/2010. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.